Recently, while kicking off a new research project with a longstanding pharma client, a familiar question resurfaced: what, precisely, qualifies a physician as working within a center of excellence (CoE)? More specifically, who is really a "CoE physician?"
The therapeutic category (TC) under consideration is a rare disease straddling two medical specialties, making the question particularly pertinent. Having conducted considerable research in this TC over the years, we found ourselves revisiting assumptions about which physicians should qualify as CoE practitioners, particularly as healthcare systems, clinical affiliations and referral networks continue to evolve.
It struck me that, for an acronym so routinely thrown around in pharma market research, center of excellence remains remarkably open to interpretation.
For example, consider a physician practicing in an outpatient office affiliated with Brigham and Women's Hospital in Boston, or Penn Medicine in Philadelphia. Both are institutions of considerable clinical and academic reputation. But does affiliation alone confer CoE status? Does affiliation with a prestigious institution automatically translate into disease-specific expertise, substantial patient volume or access to multidisciplinary resources?
And should it?
These are not merely academic questions. How we define CoE physicians influences whom we recruit for research, how we interpret their perspectives and, ultimately, the commercial decisions informed by their experiences and input.
The ambiguity is hardly new. In their 2017 article, Centers of excellence in healthcare institutions: what they are and how to assemble them, published in BMC Health Services Research, James Elrod and John Fortenberry characterize CoEs as specialized programs concentrating clinical expertise and resources around particular medical conditions, delivered through comprehensive, interdisciplinary care.
More revealingly, they observe that, with limited exceptions, healthcare institutions can adopt the designation without formal certification. Excellence, apparently, can sometimes be conferred by the advertising department.
Yet credible designation systems certainly exist. The Cystic Fibrosis Foundation accredits specialist care centers with dedicated multidisciplinary teams. The National Cancer Institute designates cancer centers according to demanding research criteria, although this designation should not be confused with certification of every clinical service. Meanwhile, the National Organization for Rare Disorders operates a network of designated institutions committed to improving rare disease diagnosis, treatment and research.
These programs demonstrate that excellence can be assessed systematically. They also illustrate a complication: different organizations recognize different capabilities. Research leadership, clinical infrastructure, multidisciplinary coordination and disease-specific experience are related attributes, but hardly synonymous.
The conventional CoE profile is familiar: an academic medical center, substantial specialist staffing, sophisticated diagnostic capabilities, multidisciplinary collaboration and a relatively high concentration of relevant patients. These characteristics represent a reasonable starting point. They do not necessarily establish the expertise of every physician working under an institution's banner.
Imagine two clinicians. One works within a prestigious academic healthcare system but personally manages relatively few patients with a particular rare disease. Another practices at a regional hospital, treats considerably more such patients and coordinates referrals across several institutions. The latter's publication record is modest, and their institution's name seldom features prominently at international congresses.
Which physician belongs in our COE sample?
Institutional affiliation is certainly relevant, but it cannot substitute for understanding an individual's clinical responsibilities, patient caseload, treatment authority and access to specialist resources.
Nor is expertise necessarily confined to an academic campus. The European Reference Networks, established to address rare and complex conditions, connect specialist centers across national boundaries. By October 2025, their 24 networks encompassed more than 1,600 specialized centers across 375 hospitals. Their model allows expertise to travel between institutions, rather than obliging every patient to do so.
Excellence, increasingly, may be better understood as a clinical ecosystem than a prestigious address.
For pharma market researchers, this distinction has considerable consequences. Consider a study exploring treatment adoption in a rare disease. If recruitment disproportionately favors academic specialists, respondents may possess earlier experience with emerging therapies, greater diagnostic sophistication, more extensive institutional support and unusually complex patient populations.
Their perspectives may be invaluable. They may also differ substantially from those of physicians managing the same condition in community or regional settings. Consequently, research may overestimate treatment readiness, underestimate operational barriers or inadequately capture the practical realities of broader clinical adoption. These are potential sampling risks, rather than inevitable outcomes, but they deserve explicit consideration.
Conversely, research exploring emerging mechanisms of action, clinical trial opportunities or highly specialized treatment decisions may quite properly prioritize physicians operating at the scientific cutting edge. The essential question is not whether CoE physicians are desirable respondents. It is whether their particular expertise corresponds to the research objective.
This becomes especially relevant when recruitment begins with a manufacturer's existing physician target list. Commercial importance, prescribing potential, key opinion leadership and CoE status may overlap, but they are not interchangeable classifications. A target list can provide a useful starting point without becoming the final arbiter of clinical excellence.
A more defensible approach would assess CoE physicians across several complementary dimensions: active clinical volume at the individual level; institutional infrastructure and multidisciplinary support; research and clinical trial involvement; referral relationships and professional influence; and (perhaps) publication bibliography.
These criteria should be weighted according to the therapeutic area and research question, rather than applied as an inflexible universal checklist.
The importance of care pathways adds another dimension. In their 2019 article, Centers of Excellence: Criteria and Comprehensive Clinical Pathways, Matthew Pakizegee and Richard Stefanacci emphasize the need for clearer CoE criteria and better coordination between specialist centers and community practitioners. Their discussion highlights how specialist institutions can influence care beyond the patients treated within their own facilities.
For marketing teams in pharma, this distinction matters. A physician may be important because of personal prescribing volume, participation in clinical research, referral influence or contribution to evolving treatment standards. Each represents a different form of relevance. For those of us in I&A, the challenge is to distinguish these roles before recruitment, document qualification criteria transparently and interpret findings with appropriate regard for the composition of the sample.
There is also a temporal consideration. Physicians relocate, healthcare systems consolidate, specialist programs expand and referral patterns change. A classification developed several years earlier may no longer reflect clinical reality. Excellence, unlike an honorary doctorate, requires periodic re-examination.
None of this diminishes the considerable contribution of genuine centers of excellence. Their role in advancing specialist care, scientific understanding and therapeutic innovation is indispensable. Indeed, Orphanet, which maintains information about rare disease expert centers and networks, explicitly cautions that its listings are not exhaustive and that appropriate specialist care may exist elsewhere. It is a useful reminder that even authoritative directories cannot capture every concentration of clinical expertise.
My own experience suggests that identifying CoE physicians should begin with a more fundamental question: what specific expertise, capabilities and influence are we seeking to understand in this particular market, for this particular research engagement?
I would be interested to learn how colleagues in pharmaceutical marketing, commercial strategy, I&A, and respondent recruitment navigate these distinctions. What criteria have proved most useful? How do you distinguish institutional affiliation from genuine disease-specific expertise? And when does a highly experienced community specialist deserve recognition alongside physicians working within the physical walls of a renowned academic centers?
Perhaps the geography of excellence is more complicated than the institutional map suggests. After all, a CoE ought to be considerably more than a distinguished postal code.